These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 38913230)
1. Prognostic significance of MRI contrast enhancement in newly diagnosed glioblastoma, IDH-wildtype according to WHO 2021 classification. Roux A; Elia A; Hudelist B; Benzakoun J; Dezamis E; Parraga E; Moiraghi A; Simboli GA; Chretien F; Oppenheim C; Zanello M; Pallud J J Neurooncol; 2024 Sep; 169(2):445-455. PubMed ID: 38913230 [TBL] [Abstract][Full Text] [Related]
2. Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma. Molinaro AM; Hervey-Jumper S; Morshed RA; Young J; Han SJ; Chunduru P; Zhang Y; Phillips JJ; Shai A; Lafontaine M; Crane J; Chandra A; Flanigan P; Jahangiri A; Cioffi G; Ostrom Q; Anderson JE; Badve C; Barnholtz-Sloan J; Sloan AE; Erickson BJ; Decker PA; Kosel ML; LaChance D; Eckel-Passow J; Jenkins R; Villanueva-Meyer J; Rice T; Wrensch M; Wiencke JK; Oberheim Bush NA; Taylor J; Butowski N; Prados M; Clarke J; Chang S; Chang E; Aghi M; Theodosopoulos P; McDermott M; Berger MS JAMA Oncol; 2020 Apr; 6(4):495-503. PubMed ID: 32027343 [TBL] [Abstract][Full Text] [Related]
3. Leptomeningeal metastases in isocitrate dehydrogenase-wildtype glioblastomas revisited: Comprehensive analysis of incidence, risk factors, and prognosis based on post-contrast fluid-attenuated inversion recovery. Park YW; Jang G; Kim SB; Choi K; Han K; Shin NY; Ahn SS; Chang JH; Kim SH; Lee SK; Jain R Neuro Oncol; 2024 Oct; 26(10):1921-1932. PubMed ID: 38822538 [TBL] [Abstract][Full Text] [Related]
4. Rethinking extent of resection of contrast-enhancing and non-enhancing tumor: different survival impacts on adult-type diffuse gliomas in 2021 World Health Organization classification. Park YW; Kim S; Han K; Ahn SS; Moon JH; Kim EH; Kim J; Kang SG; Kim SH; Lee SK; Chang JH Eur Radiol; 2024 Feb; 34(2):1376-1387. PubMed ID: 37608093 [TBL] [Abstract][Full Text] [Related]
5. Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients. Hallaert G; Pinson H; Vanhauwaert D; Van den Broecke C; Van Roost D; Boterberg T; Kalala JP Surg Oncol; 2020 Dec; 35():515-519. PubMed ID: 33152608 [TBL] [Abstract][Full Text] [Related]
6. Relevance of calcification and contrast enhancement pattern for molecular diagnosis and survival prediction of gliomas based on the 2016 World Health Organization Classification. Michiwaki Y; Hata N; Mizoguchi M; Hiwatashi A; Kuga D; Hatae R; Akagi Y; Amemiya T; Fujioka Y; Togao O; Suzuki SO; Yoshimoto K; Iwaki T; Iihara K Clin Neurol Neurosurg; 2019 Dec; 187():105556. PubMed ID: 31639630 [TBL] [Abstract][Full Text] [Related]
7. Surgical management and outcome of newly diagnosed glioblastoma without contrast enhancement (low-grade appearance): a report of the RANO resect group. Karschnia P; Dietrich J; Bruno F; Dono A; Juenger ST; Teske N; Young JS; Sciortino T; Häni L; van den Bent M; Weller M; Vogelbaum MA; Morshed RA; Haddad AF; Molinaro AM; Tandon N; Beck J; Schnell O; Bello L; Hervey-Jumper S; Thon N; Grau SJ; Esquenazi Y; Rudà R; Chang SM; Berger MS; Cahill DP; Tonn JC Neuro Oncol; 2024 Jan; 26(1):166-177. PubMed ID: 37665776 [TBL] [Abstract][Full Text] [Related]
8. Impact of frailty on survival glioblastoma, IDH-wildtype patients. Hudelist B; Elia A; Roux A; Paun L; Schumacher X; Hamza M; Demasi M; Moiraghi A; Dezamis E; Chrétien F; Benzakoun J; Oppenheim C; Zanello M; Pallud J J Neurooncol; 2024 Aug; 169(1):61-72. PubMed ID: 38762828 [TBL] [Abstract][Full Text] [Related]
9. Differentiating between glioblastomas with and without isocitrate dehydrogenase gene mutation by findings on conventional magnetic resonance images. Shimizu T; Matsushima S; Fukasawa N; Akasaki Y; Mori R; Ojiri H J Clin Neurosci; 2020 Jun; 76():140-144. PubMed ID: 32291242 [TBL] [Abstract][Full Text] [Related]
10. Prognostic relevance of radiological findings on early postoperative MRI for 187 consecutive glioblastoma patients receiving standard therapy. Rykkje AM; Carlsen JF; Larsen VA; Skjøth-Rasmussen J; Christensen IJ; Nielsen MB; Poulsen HS; Urup TH; Hansen AE Sci Rep; 2024 May; 14(1):10985. PubMed ID: 38744979 [TBL] [Abstract][Full Text] [Related]
11. Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas. Moon HH; Kim HS; Park JE; Kim YH; Kim JH BMC Cancer; 2021 Jun; 21(1):654. PubMed ID: 34074252 [TBL] [Abstract][Full Text] [Related]
12. Supramaximal resection: retrospective study on IDH-wildtype Glioblastomas based on the new RANO-Resect classification. Tropeano MP; Raspagliesi L; Bono BC; Baram A; Rossini Z; Franzini A; Navarria P; Clerici E; Bellu L; Simonelli M; Scorsetti M; Riva M; Politi LS; Pessina F Acta Neurochir (Wien); 2024 Apr; 166(1):196. PubMed ID: 38676720 [TBL] [Abstract][Full Text] [Related]
13. Predictive value of MGMT promoter methylation on the survival of TMZ treated Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600 [TBL] [Abstract][Full Text] [Related]
14. Comparison of Genetic Profiles and Prognosis of High-Grade Gliomas Using Quantitative and Qualitative MRI Features: A Focus on G3 Gliomas. Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST Korean J Radiol; 2021 Feb; 22(2):233-242. PubMed ID: 32932560 [TBL] [Abstract][Full Text] [Related]
15. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status. Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492 [TBL] [Abstract][Full Text] [Related]
16. Influence of supramarginal resection on survival outcomes after gross-total resection of IDH-wild-type glioblastoma. Vivas-Buitrago T; Domingo RA; Tripathi S; De Biase G; Brown D; Akinduro OO; Ramos-Fresnedo A; Sabsevitz DS; Bendok BR; Sherman W; Parney IF; Jentoft ME; Middlebrooks EH; Meyer FB; Chaichana KL; Quinones-Hinojosa A J Neurosurg; 2022 Jan; 136(1):1-8. PubMed ID: 34087795 [TBL] [Abstract][Full Text] [Related]
17. Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide. Berger K; Turowski B; Felsberg J; Malzkorn B; Reifenberger G; Steiger HJ; Budach W; Haussmann J; Knipps J; Rapp M; Hänggi D; Sabel M; Mijderwijk HJ; Kamp MA J Cancer Res Clin Oncol; 2021 Jan; 147(1):253-262. PubMed ID: 32748120 [TBL] [Abstract][Full Text] [Related]
18. Positive influence of partial resection on overall survival of patients with overlapping glioblastomas. Quick-Weller J; Tritt S; Baumgarten P; Konczalla J; Kashefiolasl S; Noack A; Tichy J; Seifert V; Marquardt G Clin Neurol Neurosurg; 2017 Oct; 161():22-28. PubMed ID: 28837843 [TBL] [Abstract][Full Text] [Related]
19. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas. Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161 [TBL] [Abstract][Full Text] [Related]